Clinical Trials Logo

Renal Insufficiency, Chronic clinical trials

View clinical trials related to Renal Insufficiency, Chronic.

Filter by:

NCT ID: NCT02885545 Withdrawn - Clinical trials for Chronic Kidney Disease

The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial

STOP-HARM
Start date: September 2016
Phase: Phase 4
Study type: Interventional

Patients with severe chronic kidney disease (CKD) who develop atrial fibrillation are at high risk for stroke. The use of blood thinking medication in dialysis patients is controversial and warfarin carries a serious risk for major bleeding. The Watchman device may be an ideal therapy for this population as after implantation it allows for the discontinuation of blood thinners, thereby reducing the risk of bleeding.

NCT ID: NCT02848508 Withdrawn - Clinical trials for Renal Insufficiency, Chronic

Metformin in Moderate and Severe Renal Failure (CKD 3-4): A Follow-up Study

METsuiviIRC
Start date: March 16, 2016
Phase: Phase 2
Study type: Interventional

To validate on the mid-term in moderate and severe renal failure (CKD 3-4) a nomogram to adapt a fixed metformin daily posology according to renal function on the basis of the first short-term study made by the investigators.

NCT ID: NCT02806362 Withdrawn - Clinical trials for Chronic Hepatitis C Virus

Study of Ombitasvir/Paritaprevir/Ritonavir in Japanese Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection With End Stage Renal Disease (ESRD) on Hemodialysis (HD)

GIFT-R
Start date: September 2016
Phase: Phase 3
Study type: Interventional

The purpose of this multicenter, single-arm, combination-drug study, which includes 12 weeks of treatment and 24 weeks of follow-up, is to evaluate the safety, efficacy and pharmacokinetics of ombitasvir/paritaprevir/ritonavir in Japanese adults infected with HCV GT1b, who are treatment-naïve or treatment-experienced to an IFN-based regimen and who have ESRD on HD.

NCT ID: NCT02778295 Withdrawn - Clinical trials for Chronic Kidney Disease

Biomarker for Patients With Fabry Disease (BioFabry)

BioFabry
Start date: August 20, 2018
Phase:
Study type: Observational

Development of a new mass spectrography-based biomarker for the early and sensitive diagnosis of Fabry disease from the blood

NCT ID: NCT02599844 Withdrawn - Hypertension Clinical Trials

Impact of Pediatric Acute Renal Injury in Severe Sepsis in Young Adults

IMPRESS-YA
Start date: December 2015
Phase:
Study type: Observational

Sepsis is the most common cause of childhood death worldwide. Millions of children survive, but are left with impaired health. Sepsis-related Acute Kidney Injury (sAKI) is increasingly recognized as a significant factor associated with long-term mortality among different patient populations. Renal dysfunction and subsequent chronic kidney disease is implicated in the development of hypertension and cardiovascular disease. The investigators overall hypothesis is that, in the pediatric population, sepsis-related AKI will have unrecognized, long-term consequences with regard to kidney function, endothelial function, blood pressure control, and overall health.

NCT ID: NCT02598674 Withdrawn - Hypertension Clinical Trials

Severe Sepsis in Children - IMPRESS-C

IMPRESS-C
Start date: October 2019
Phase:
Study type: Observational

Sepsis is the most common cause of childhood death worldwide. Millions of children survive, but are left with impaired health. Sepsis-related Acute Kidney Injury (sAKI) is increasingly recognized as a significant factor associated with long-term mortality among different patient populations. Renal dysfunction and subsequent chronic kidney disease is implicated in the development of hypertension and cardiovascular disease. The investigators overall hypothesis is that, in the pediatric population, sepsis-related AKI will have unrecognized, long-term consequences with regard to kidney function, endothelial function, blood pressure control, and overall health.

NCT ID: NCT02563665 Withdrawn - Clinical trials for CKD With Hepatitis C

Safety and Efficacy of Sofosbuvir Based Antiviral Regimen for Treating Hepatitis C in Patients With Moderate to Advanced Chronic Kidney Disease and Patients Receiving Renal Replacement Therapy

Start date: September 2015
Phase:
Study type: Observational

All patients with chronic kidney disease (stages 3, 4 and 5) and chronic dialysis patients with HCV infection attending nephrology and Hepatology OPD or getting outpatient dialysis at the dialysis unit of ILBS.

NCT ID: NCT02473705 Withdrawn - Clinical trials for Cardiovascular Disease

Pathways to Improving Functional Capacity in Older Patients With Chronic Kidney Disease and Cardiovascular Disease

CKD&CAD
Start date: January 2016
Phase: N/A
Study type: Interventional

The purpose of this research study is to study the effect of fish oil and bicarbonate (baking soda) on exercise. In this study fish oil, bicarbonate or both will be compared to placebo to see if study participants increase exercise capacity.

NCT ID: NCT02372721 Withdrawn - Hypertension Clinical Trials

Long Term Impact of Pediatric Acute Renal Injury in Severe Sepsis

IMPRESS
Start date: March 2015
Phase: N/A
Study type: Observational

Sepsis is the most common cause of childhood death worldwide. Millions of children survive, but are left with impaired health. Sepsis-related Acute Kidney Injury (sAKI) is increasingly recognized as a significant factor associated with long-term mortality among different patient populations. Renal dysfunction and subsequent chronic kidney disease is implicated in the development of hypertension and cardiovascular disease. The investigators overall hypothesis is that, in the pediatric population, sepsis-related AKI will have unrecognized, long-term consequences with regard to kidney function, endothelial function, blood pressure control, and overall health.

NCT ID: NCT02333955 Withdrawn - Clinical trials for Chronic Kidney Disease

A Phase 2 Extension of Study GCS-100-CS-4003

Start date: January 2015
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to determine the safety and tolerability of extended dosing with a fixed dose of GCS-100 3 mg IV push in patients with Chronic Kidney Disease (CKD).